{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T15:56:05Z","timestamp":1722009365769},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.ejca.2003.10.022","type":"journal-article","created":{"date-parts":[[2004,1,13]],"date-time":"2004-01-13T10:24:13Z","timestamp":1073989453000},"page":"508-514","source":"Crossref","is-referenced-by-count":11,"title":["Phase I trial of UFT\/leucovorin and irinotecan in patients with advanced cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"M.L.","family":"Veronese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Redlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Algazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Giantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.G.","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"O'Dwyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2003.10.022_BIB1","first-page":"343","article-title":"Pharmacokinetics and metabolism of ftorafur in man","volume":"63","author":"Au","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ejca.2003.10.022_BIB2","first-page":"4039","article-title":"Metabolic activation of R,S-1-[tetrahydro-2-furanyl]-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes","volume":"43","author":"El Sayed","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.10.022_BIB3","first-page":"936","article-title":"Clinical pharmacology of combined oral uracil and ftorafur","volume":"20","author":"Ho","year":"1992","journal-title":"Drug Metab Disp"},{"key":"10.1016\/j.ejca.2003.10.022_BIB4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00254241","article-title":"Report on nationwide pooled data and cohort investigation in UFT phase II study","volume":"22","author":"Ota","year":"1988","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ejca.2003.10.022_BIB5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1005808822565","article-title":"Phase I trial of uracil-tegafur (UFT) plus oral leucovorin\u201414-day schedule","volume":"15","author":"Pazdur","year":"1997","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2003.10.022_BIB6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s002800050432","article-title":"A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer","volume":"37","author":"Meropol","year":"1996","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ejca.2003.10.022_BIB7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/00001813-199609000-00002","article-title":"Phase I trias of uracil-tegafur (UFT) using 5 and 28 day administration schedules\u2014demonstration of schedule dependent toxicities","volume":"7","author":"Pazdur","year":"1996","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.ejca.2003.10.022_BIB8","first-page":"1461","article-title":"Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil","volume":"2","author":"Muggia","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.10.022_BIB9","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.1994.12.11.2296","article-title":"Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma","volume":"12","author":"Pazdur","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/1097-0142(19950201)75:3<782::AID-CNCR2820750306>3.0.CO;2-I","article-title":"A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer","volume":"75","author":"Saltz","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2003.10.022_BIB11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/0959-8049(95)00487-4","article-title":"Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study","volume":"31A","author":"Gonzales-Baron","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2003.10.022_BIB12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0305-7372(94)90011-6","article-title":"Topoisomerase I inhibitors: topotecan and irinotecan","volume":"20","author":"Creemers","year":"1994","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejca.2003.10.022_BIB13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","article-title":"Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-na\u0131&#x0308;ve patients and patients pretreated with fluorouracil-based chemotherapy","volume":"15","author":"Rougier","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2003.10.022_BIB15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","article-title":"Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer","volume":"352","author":"Cunningham","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2003.10.022_BIB16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0006-2952(97)00541-8","article-title":"Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line","volume":"55","author":"Guichard","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejca.2003.10.022_BIB17","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0959-8049(99)00222-1","article-title":"Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines","volume":"35","author":"Mans","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2003.10.022_BIB18","first-page":"1323","article-title":"Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro","volume":"4","author":"Aschele","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.10.022_BIB19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metatstatic colorectal cancer. Irinotecan study group","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejca.2003.10.022_BIB20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2003.10.022_BIB21","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/0959-8049(95)00212-2","article-title":"CPT-11 (Irinotecan) in the treatment of colorectal cancer","volume":"31A","author":"Armand","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2003.10.022_BIB22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","article-title":"Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients","volume":"13","author":"Abigerges","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1749-6632.1996.tb26398.x","article-title":"CPT11. The European experience","volume":"803","author":"Armand","year":"1996","journal-title":"Ann N Y Acdd Sci."},{"key":"10.1016\/j.ejca.2003.10.022_BIB24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.tpj.6500012","article-title":"Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy","volume":"1","author":"Pullarkat","year":"2001","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.ejca.2003.10.022_BIB25","first-page":"907","article-title":"Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514","volume":"16","author":"Zervos","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB26","first-page":"4618","article-title":"Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid","volume":"51","author":"Moran","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.10.022_BIB27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008337900349","article-title":"MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil","volume":"22","author":"Toffoli","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2003.10.022_BIB29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acid Res."},{"key":"10.1016\/j.ejca.2003.10.022_BIB30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/clinchem\/46.7.907","article-title":"Accurate and rapid multiplex heteroduplexing method for genotyping key enzymes involved in folate\/homocysteine metabolism","volume":"46","author":"Barbaux","year":"2000","journal-title":"Clin Chem."},{"key":"10.1016\/j.ejca.2003.10.022_BIB31","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/bjc.1990.431","article-title":"Phase II trial of UFT in advanced colorectal and gastric cancer","volume":"62","author":"Malik","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2003.10.022_BIB32","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2002.10.129","article-title":"Randomized comparative study of tegafur\/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"Carmichael","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB33","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2002.04.123","article-title":"Multicenter phase III study of uracil\/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer","volume":"20","author":"Douillard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB34","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer. Results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Onc"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2003.10.022_BIB35","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0959-8049(01)00415-4","article-title":"On behalf of the Xeloda Colorectal Cancer Group","volume":"38","author":"Twelves","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2003.10.022_BIB36","first-page":"1018","article-title":"Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI Group study 40986","volume":"22","author":"Kohne","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB37","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2001.19.18.3801","article-title":"Mortality associated with irinotecan plus bolus fluorouracil\/leucovorin","volume":"19","author":"Rothemberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB38","first-page":"1022","article-title":"Randomized phase II trial of capecitabine plus irinotecan (Caplri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC)","volume":"22","author":"Grothey","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl. 12","key":"10.1016\/j.ejca.2003.10.022_BIB39","first-page":"23","article-title":"Can capecitabine replace 5-FU\/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?","volume":"16","author":"Twelves","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2003.10.022_BIB40","first-page":"643","article-title":"A phase I\/II study of CPT-11 in combination with capecitabine as first-line chemotherapy for metastatic colorectal cancer","volume":"21","author":"Kerr","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl. 12","key":"10.1016\/j.ejca.2003.10.022_BIB41","first-page":"12","article-title":"Capecitabine\/irinotecan in colorectal cancer","volume":"16","author":"Kerr","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2003.10.022_BIB42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0006-2952(97)00541-8","article-title":"Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line","volume":"55","author":"Guichard","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejca.2003.10.022_BIB43","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0006-2952(98)00205-6","article-title":"Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity","volume":"56","author":"Pavillard","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejca.2003.10.022_BIB44","first-page":"193","article-title":"Enhanced antitumour activity of SN-38, an active metabolite of CPT-11, and 5-fluorouracil combination for human colorectal cancer cell lines","volume":"12","author":"Funakoshi","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB45","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/S0959-8049(01)00321-5","article-title":"Phase I trial of weekly irinotecan combined with UFT as second line treatment for advanced colorectal cancer","volume":"37","author":"Alonso","year":"2001","journal-title":"Eur J Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2003.10.022_BIB46","first-page":"45","article-title":"Phase I\/II study of oral uracil\/tegafur (UFT), leucovorin (LV) and irinotecan (CPT-11) in patients with advanced colorectal cancer","volume":"11","author":"Hill","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB47","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB48","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1200\/JCO.2001.19.20.4081","article-title":"Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer","volume":"19","author":"Stevenson","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2003.10.022_BIB49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0169-5002(01)00258-6","article-title":"The role of UFT and the combination of UFT\/leucovorin in non small cell lung cancer","volume":"34","author":"Langer","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2003.10.022_BIB50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.1992.10.1.16","article-title":"A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer","volume":"10","author":"Fukuoka","year":"1992","journal-title":"J Clin Oncol"},{"issue":"Suppl. 9","key":"10.1016\/j.ejca.2003.10.022_BIB51","first-page":"25","article-title":"Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer","volume":"16","author":"Rocha Lima","year":"2002","journal-title":"Oncology"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2003.10.022_BIB52","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0959-8049(99)81478-6","article-title":"Phase I and pharmacokinetic study of irinotecan (CPT-11) given by 24 hours infusion plus oral uracil\/tegafur (UFT) in patients with lung cancer","volume":"35","author":"Yamazaki","year":"1999","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804903009377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804903009377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T20:34:01Z","timestamp":1585427641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804903009377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0959804903009377"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2003.10.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}